FIELD: molecular biology; biochemistry; medicine; pharmacology.
SUBSTANCE: invention represents the use of (+)-usnic acid derivatives of formula I a–c as an agent for inhibiting reproduction of SARS-CoV-2 virus strains. I a–c.
EFFECT: invention provides effective reduction of SARS-CoV-2 virus titre (strains hCoV-19/Australia/VIC01/2020, hCoV-19/Russia/PSK-2804/2021, hCoV-19/Russia/Moscow171619-031221/2021, hCov-19/Russia/Moscow-49415/2022, hCoV-19/Russia/TOM-SRC-8663/2023, hCov-19/Russia/TYU-SRC-8642/2023) in cell culture.
2 cl, 1 dwg, 6 tbl, 13 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PLASMID GENETIC CONSTRUCT pET21a_SKP, WHICH PROVIDES EXPRESSION IN ESCHERICHIA COLI PROKARYOTIC SYSTEM OF RECOMBINANT SKP PROTEIN, AND RECOMBINANT PROTEIN SKP HAVING BROADLY NEUTRALIZING PROPERTIES OF SINGLE-DOMAIN NANOANTIBODY AGAINST SARS-CoV-2 | 2024 |
|
RU2839376C1 |
| ETHYL ESTER OF 2-(ADAMANTAN-1-yl)-3-BROMO-7-OXO-4,7-DIHYDROPYRAZOLO[1,5-a]PYRIMIDINE-6-CARBOXYLIC ACID, HAVING ANTIVIRAL ACTION ON SARS-CoV-2 CORONAVIRUS | 2024 |
|
RU2839407C1 |
| HEAVY-CHAIN MONOCLONAL ANTIBODIES SPECIFICALLY BINDING TO S PROTEIN OF SARS-CoV-2 VIRUS, AND METHOD OF USING THEM FOR TREATMENT OF DISEASES CAUSED BY DIFFERENT VARIANTS OF SARS-CoV-2 VIRUS | 2024 |
|
RU2836313C1 |
| 3-BENZYL-5-METHYL-6-(PHENYLTHIO)-[1,2,4]TRIAZOLO[1,5-a]PYRIMIDIN-7(3H)-ONE, WHICH HAS ANTIVIRAL ACTIVITY AGAINST THE SARS-CoV2 CORONAVIRUS | 2022 |
|
RU2808622C1 |
| STRAIN OF HCOV-19/RUSSIA/OMSK-202118-1707/2020 OF SARS-COV-2 CORONAVIRUS, IMMUNOSORBENT CONTAINING PURIFIED WHOLE VIRION ANTIGEN OBTAINED ON BASIS OF SPECIFIED STRAIN AND ISA TEST SYSTEM FOR DETECTING ANTIBODIES OF CLASSES M, G AND A TO SARS CORONAVIRUS-COV-2 USING SPECIFIED IMMUNOSORBENT | 2021 |
|
RU2752862C1 |
| RECOMBINANT PLASMID pVEAL3-XBB.1.5, WHICH PROVIDES SYNTHESIS AND SECRETION OF RECEPTOR-BINDING DOMAIN RBD S OF SARS-CoV-2 PROTEIN OF VARIANT XBB.1.5, AND RECOMBINANT STRAIN CHO-XBB.1.5 - PRODUCER OF RECEPTOR-BINDING DOMAIN RBD S PROTEIN SARS-CoV-2 VERSION XBB.1.5 INTENDED FOR PRODUCING IMMUNOBIOLOGICAL PREPARATIONS | 2024 |
|
RU2839373C1 |
| RECOMBINANT STRAIN SEN-SDELTA(M) OF SENDAI VIRUS, PRODUCING S-PROTEIN SARS-CoV-2 AND USED TO PRODUCE INTRANASAL VACCINE AGAINST COVID-19 | 2024 |
|
RU2837536C1 |
| INTEGRATIVE PLASMID VECTOR pVEAL3-RBDdel, PROVIDING SYNTHESIS AND SECRETION OF RECOMBINANT PROTEIN OF RECEPTOR-BINDING DOMAIN RBDdelta OF CORONAVIRUS SARS-CoV-2 IN MAMMALIAN CELLS, RECOMBINANT CELL LINE STRAIN CHO-K1-RBDdelta AND RECOMBINANT PROTEIN RBDdelta SARS-CoV-2 PRODUCED BY CELL LINE STRAIN | 2023 |
|
RU2816175C1 |
| METHOD OF PRODUCING RECOMBINANT STRAIN OF ENTEROCOCCUS L3-SARS"XBB.1.5" BASED ON BIOLOGICALLY ACTIVE STRAIN OF ENTEROCOCCUS FAECIUM L3 | 2023 |
|
RU2840971C1 |
| TEST SYSTEM FOR DETECTION OF SARS-CoV-2 OF OMICRON LINE BY SINGLE-STEP POLYMERASE CHAIN REACTION WITH REVERSE TRANSCRIPTION | 2021 |
|
RU2772362C1 |
